Chordate Medical has so far received formal notifications from four of the company's ten largest shareholders: Sifonen, Hawoc, the Brandberg family, and Tommy Hedberg, who, together with the management team, have announced that they will exercise their warrants in TO8 at 100 percent. Once this is completed, approximately 42 percent of the series TO8 warrants will have been exercised.
These four of the ten largest shareholders, together with the company’s management team, control approximately 40 percent of the shares in Chordate.
It is possible to redeem TO8 for subscription of new shares from November 4, 2024, until November 18, 2024, or to sell the options before November 14, 2024. If all TO8 series warrants are exercised, the company will receive approximately 6.1 MSEK before issuance costs.
“The support from our largest shareholders – and my colleagues in the management team – is a very important vote of confidence in achieving a positive outcome from TO8. It is crucial that we secure as much capital as possible from the options, and every shareholder's contribution is equally important,” says Anders Weilandt, CEO of Chordate.
